Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

Myelodysplastic Syndromes Clinical Trial

Official title:

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00186576
• Other study ID #: BMT128
• Secondary ID: 75826BMT128
• Status: Completed
• Phase: N/A
• First received: September 14, 2005
• Last updated: October 13, 2010
• Start date: December 2001
• Est. completion date: July 2010

Study information

• Verified date: October 2010
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Description:

Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Other known NCT identifiers

• NCT00052546

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 2010
• Est. primary completion date: March 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:- Myelodysplastic Syndromes

• Myeloproliferative Disorders

• HLA matched donor available

Exclusion Criteria:- organ dysfunction

• HIV positive

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Blood and Marrow Transplant (BMT)
• Disease
• Myelodysplastic Syndromes
• Myelodysplastic Syndromes (MDS)
• Myeloproliferative Disorders
• Myeloproliferative Disorders (MPD)
• Preleukemia
• Syndrome

Intervention

Procedure:
• nonmyeloablative allogeneic hematopoietic cell transplant

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T, Maris MB, Agura ED, Chauncey TR, Wong RM, Forman SJ, Petersen FB, Wade JC, Epner E, Bruno B, Bethge WA, Curtin PT, Maloney DG, Blume KG, Storb RF. Reduced-intensity conditioning followed by — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of transplant		1 year	No
Secondary	safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion		1 year	Yes